- Disease
- Tuesday, 23 Jun 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
"AGEN1181 is an Fc-engineered anti-CTLA-4 that has shown exciting clinical activity in an early phase 1 clinical trial, which was recently presented at ASCO," said Dr. Antoine Tanne, Lead Scientist, Agenus Immune Biology Team. "Today, at AACR, we report that combinations with AGEN1181 demonstrate curative responses in preclinical models resistant to anti-PD-1. These data illustrate the potential of combining allogeneic cell therapies with checkpoint antibodies, such as AGEN1181, to deliver curative benefit in difficult to treat settings."
Related Industry Updates
G7 to use all policy tools against fast-spreading coronavirus
Mar 03, 2020
Strict lockdown pushes South African PMI to a new record low in April
May 06, 2020
Managing Your Orthopaedic Care during the COVID-19 Pandemic
May 06, 2020
Facebook, Google recommended their San Francisco Bay Employees to work from home as coronavirus spreads
Mar 06, 2020
Indian Prime Minister Narendra Modi to provide $266 billion to boost pandemic-hit economy
May 13, 2020
The UK finance minister warns economy could shrink by 30% because of the coronavirus lockdown
Apr 13, 2020
Tumor Ablation Market 2021 Strong Revenue, Competitive Outlook by Top Competitors And Forecast To 2027
Apr 27, 2021
Follow us on
